UNION PACIFIC CORP

**Signal Note: Driehaus Growth Position in UNP** This position acquisition appears misaligned with Driehaus's biotech-focused mandate, suggesting either portfolio diversification or conviction on railroad logistics benefiting from specific sector tailwinds (potentially pharma distribution/supply chain resilience). The $637K stake is modest relative to typical growth fund positioning and lacks clear biotech catalysts, warranting monitoring for additional context on whether this reflects a broader infrastructure thesis or tactical hedging.

**Signal Note: Eventide Biotech-Focused Fund Adds Transportation Infrastructure** This position represents a notable diversification move by Eventide into non-healthcare infrastructure, likely driven by valuation or portfolio rebalancing rather than biotech-specific catalysts. Union Pacific's exposure to pharmaceutical logistics and cold-chain distribution networks supporting biotech supply chains may offer indirect healthcare exposure, though this represents a strategic shift away from Eventide's core biotech mandate.